Patient characteristics and treatment patterns in chronic myeloid leukemia: Evidence from a multi-country retrospective medical record chart review study

International Journal of Hematology

Volumn 95, Issue 3, 2012, Pages 263-273

  Mitra, Debanjali ^a   Candrilli, Sean D ^a   Trask, Peter C ^b   Kaye, James A ^a   Iyer, Shrividya ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b PFIZER INC   (United States)

Author keywords

Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Treatment patterns

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GERMANY; HEADACHE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PHILADELPHIA 1 CHROMOSOME; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED KINGDOM; UNITED STATES;

EID: 84863004514     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1010-4     Document Type: Article

References (7)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER cancer statistics review, 1975-2007. Bethesda: National Cancer Institute; 2009. http://seer.cancer.gov/csr/1975-2007/results-merged/ sect-13-leukemia.pdf. Accessed 10 Nov 2011.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
3. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-8. (Pubitemid 38451654)
4. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-99. (Pubitemid 14141296)
5. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. (Pubitemid 17055592)
6. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355: 2408-17. (Pubitemid 44903745)
7. Gleevec (imatinib) FDA label approved. April, 2011. http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/021588s030s031lbl.pdf. Accessed 1 Feb 2012.